Shares of Bristol-Myers Squibb Company (NYSE:BMY) saw an erosion of -1 points in recent session. During the trading, the value of each share was $70.73, dropping -1.39%. The shares saw high fund-flow as the composite value of all the upticks was $189.88 million and the total value of all the downticks was a mere $42.82 million. The net money flow was seen at $147.06 million and the up/down ratio was measured at 4.43. On a weekly basis the shares of the shares have recorded a change of -2.64%.The block trade which occurred today had $149.15 million in upticks and $3.03 million in downticks with the up/down ratio climbing to 49.23. $146.12 million was the net money flow of the block transaction.
Bristol-Myers Squibb Company has lost 2.73% in the last five trading days and dropped 0.59% in the last 4 weeks. Bristol-Myers Squibb Company is up 13.15% in the last 3-month period. Year-to-Date the stock performance stands at 3.34%.
Currently the company Insiders own 0.24% of Bristol-Myers Squibb Company shares according to the proxy statements. In the past twelve weeks, the net percent change held by company insiders has changed by -15.67% . Institutional Investors own 74.66% of Bristol-Myers Squibb Company shares. During last six month period, the net percent change held by insiders has seen a change of -0.7%. . On the companys insider trading activities, The Securities and Exchange Commission has divulged that Elicker John E, officer (SVP, Public Affairs & IR) of Bristol Myers Squibb Co, had unloaded 11,820 shares at an average price of $72.69 in a transaction dated on June 14, 2016. The total value of the transaction was worth $859,196.
Bristol-Myers Squibb Company (NYSE:BMY) witnessed a decline in the market cap on Friday as its shares dropped 1.48% or 1.06 points. After the session commenced at $72, the stock reached the higher end at $72 while it hit a low of $70.13. With the volume soaring to 15,007,684 shares, the last trade was called at $70.67. The company has a 52-week high of $75.12. The company has a market cap of $117,970 million and there are 1,669,307,300 shares in outstanding. The 52-week low of the share price is $51.82.
Bristol-Myers Squibb Company (BMS) is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products across the world. The Companys products are sold to wholesalers, retail pharmacies, hospitals, government entities and the medical profession. The Company manufactures its products in the United States, Puerto Rico and in six foreign countries. The Company promotes the use of its products directly to healthcare professionals and providers, such as doctors, nurse practitioners, physician assistants, pharmacists, technologists, hospitals, Pharmacy Benefit Managers (PBMs) and Managed Care Organizations (MCOs). It also provides information about the use of its products to consumers in the United States through direct-to-consumer print, radio, television, and digital advertising and promotion. In addition, the Company holds rights to F001287, which is a preclinical, small-molecule IDO1-inhibitor.